CD8A and neoplasm: Demonstrating the ability of VX-765 to induce an immunoreactive TIME within human tumors, treatment of humanized mice bearing MDA-MB231 xenografts decreased CD14+ HLA-DR+ macrophages and increased activated granzyme B positive (GrB+) CD8+ T cells, with a trend (p = 0.1) towards decreased tumor size (Fig. S6g).